NORWALK, Conn., Feb. 11, 2013 /PRNewswire/ -- UBM Medica US announced today that its online community for oncology nurses and cancer care team members – TheONC.org – will be hosting a live, free webinar, "Palliative Care: Identifying the Need and Beginning the Conversation," on Monday, February 25, 2013 at 12 p.m. ET.
Hosted by Dr. James Tulsky, Chief of Palliative Care and Professor of Medicine and Nursing at Duke University, this webinar will:
- Define palliative care and describe how oncology nurses can best address patient suffering
- Focus on communication with patients around delivering bad news, discussing transitions in care, and dealing with patient distress when anti-cancer therapy is no longer effective
- Offer participants a chance to ask questions during a live question-and-answer period
Dr. Tulsky has a longstanding interest in doctor-patient communication and quality of life at the end of life, and has published widely in these areas. His current research focuses on the evaluation and enhancement of communication between oncologists and patients with advanced cancer, identification of clinical, psychosocial and spiritual trajectories of patients at the end of life, development of self-management interventions for patients with life-limiting illness, and evaluating the role of palliative care in congestive heart failure.
Launched in February 2012, TheONC is a free, online community exclusively for oncology nurses and the cancer care teams that support them. With more than 8,500 members, TheONC unites nurses in a secure environment where they can leverage their collective knowledge, nurture professional growth, and emotionally support each other. By sharing experiences and accessing free educational resources such as the palliative care webinar on TheONC, members can not only improve quality of life for themselves, but also the quality of care for the patients they treat.
For more information, or to register for this free webinar, visit TheONC at www.TheONC.org.
TheONC is supported by an unrestricted grant from Bristol-Myers Squibb.
SOURCE UBM Medica US